Cancer cells lose homeostatic flexibility because of mutations and dysregulated signaling pathways involved in maintaining homeostasis. Tuberous Sclerosis Complex 1 (TSC1) and TSC2 play a fundamental role in cell homeostasis, where signal transduction through TSC1/TSC2 is often compromised in cancer, leading to aberrant activation of mechanistic target of rapamycin complex 1 (mTORC1). mTORC1 hyperactivation increases the basal level of endoplasmic reticulum (ER) stress via an accumulation of unfolded protein, due to heightened de novo protein translation and repression of autophagy. We exploit this intrinsic vulnerability of tumor cells lacking TSC2, by treating with nelvinavir to further enhance ER stress while inhibiting the proteasome with bortezomib to prevent effective protein removal. We show that TSC2-deficient cells are highly dependent on the proteosomal degradation pathway for survival. Combined treatment with nelfinavir and bortezomib at clinically relevant drug concentrations show synergy in selectively killing TSC2-deficient cells with limited toxicity in control cells. This drug combination inhibited tumor formation in xenograft mouse models and patient-derived cell models of TSC and caused tumor spheroid death in 3D culture. Importantly, 3D culture assays differentiated between the cytostatic effects of the mTORC1 inhibitor, rapamycin, and the cytotoxic effects of the nelfinavir/bortezomib combination. Through RNA sequencing, we determined that nelfinavir and bortezomib tip the balance of ER protein homeostasis of the already ERstressed TSC2-deficient cells in favor of cell death. These findings have clinical relevance in stratified medicine to treat tumors that have compromised signaling through TSC and are inflexible in their capacity to restore ER homeostasis.
Introduction
Cancer cells often display enhanced endoplasmic reticulum (ER) stress, due to inappropriately high levels of protein synthesis, mutational load, and oxidative stress that leads to the accumulation of misfolded protein [1] . The unfolded protein response (UPR) restores ER homeostasis by slowing the rate of protein translation, targeting unfolded protein to degradation pathways (autophagy and the proteasome), and enhancing protein-folding within the ER. If the UPR fails to restore ER homeostasis in a timely manner, cell death will ensue.
Mechanistic target of rapamycin (mTOR) (commonly called mammalian target of rapamycin) functions as a key regulator of protein translation to drive cell growth. Hyperactivation of mTOR complex 1 (mTORC1) elevates ER stress through inappropriately high protein synthesis and an accumulation of unfolded protein [2] . Aberrant mTORC1 activation also potently represses autophagy (reviewed in ref. [3] ). When autophagy is compromised, the proteasome becomes the primary proteolytic pathway that removes unfolded protein aggregates, thereby restoring ER homeostasis and preventing cell death [4] .
Inactivating mutations in either Tuberous Sclerosis Complex 1 (TSC1) or TSC2 give rise to Tuberous Sclerosis (TS), a genetic disorder where patients are predisposed to mTORC1-mediated tumors in the brain, kidney, eyes, lung, heart, and skin (for review see ref. [5] ). Functional loss of TSC2 and resulting activation of mTORC1 upregulates the proteasome [6] . Consequently, we hypothesize that mTORC1-driven cancers have a higher dependency on the proteasome for survival. A feasible therapeutic strategy might be to inhibit the proteasome with the aim of increasing ER stress beyond a tolerated survival threshold. Supporting this concept, proteasome inhibitors have shown selective cytotoxicity in cancers with heightened mTORC1 [7, 8] . However, the proteasome inhibitor, bortezomib, had little efficacy as a single agent in preventing renal cystadenoma development in a Tsc2+/− mouse model [9] . This study suggested that proteasome inhibition alone is unlikely to cause cytotoxicity in mTORC1-active tumors. We therefore examined the combined effects of bortezomib with nelfinavir. Nelfinavir is an HIV protease inhibitor but has activity against a broad range of cancers. One proposed anticancer action of nelfinavir is through ER stress induction [10] . When combined with nelfinavir, bortezomib has enhanced activity against advanced hematological malignancies such as multiple myeloma, recurrent multiple myeloma, and mantle cell lymphoma [11] . Combined nelfinavir and bortezomib therapy is cytotoxic to breast cancer, acute myeloid leukemia, non-small cell lung cancer, and myeloma cancer models [12] [13] [14] , prompting several clinical trials (ClinicalTrials.gov: NCT01164709, NCT02188537, NCT01555281).
To stratify therapy, we wanted to determine whether inactivation of TSC2, a key regulator of mTORC1, would sensitize cell and tumor models to combined nelfinavir and bortezomib treatment. Previously we showed that combined treatment with nelfinavir and the autophagy inhibitor, chloroquine, was sufficient to kill cancer cell lines with a high level of mTORC1 [15] . In this study, we reveal that both in vitro and in vivo mTORC1-hyperactive tumor models are sensitive to combined nelfinavir and bortezomib-induced cytotoxicity via ER stress, while normal cells tolerate this drug combination through intact compensatory mechanisms.
Results

ER stress is elevated upon nelfinavir and bortezomib treatment in Tsc2−/− MEFs
To assess ER stress after combined nelfinavir and bortezomib treatment, we analyzed downstream ER stress markers by western blotting. As a control we employed MG132 to inhibit the proteasome. Nelfinavir and bortezomib individually enhanced ER stress in Tsc2−/− mouse embryonic fibroblasts (MEFs), as shown by increased ATF4, CHOP and GADD34 protein, while induction of these proteins in Tsc2+/+ MEFs was less evident (Fig. 1a) . Combined nelfinavir and bortezomib treatment further elevated the protein levels of ATF4, CHOP, and GADD34 compared to single drug treatment, particularly in the Tsc2−/− MEFs.
We next analyzed Xbp1 mRNA splicing, a functional readout of IRE1α activation and ER stress. Thapsigargin was employed as a control to induce ER stress. We observed more Xbp1 mRNA splicing upon nelfinavir treatment in both cell lines. Bortezomib treatment did not cause Xbp1 mRNA splicing by itself and did not further enhance splicing when combined with nelfinavir; although nelfinavir-and bortezomib-treated Tsc2−/− MEFs exhibited significantly higher levels of splicing when compared to Tsc2+/+ MEFs (Fig. 1b) . To confirm this differential ER stress induction between cells with and without Tsc2, we examined Chop and Bip mRNA levels (Fig. 1c) . In untreated cells, Chop and Bip mRNA in Tsc2−/− MEFs were fivefold and twofold higher, respectively, when compared to Tsc2+/+ MEFs, indicating that ER stress is basally elevated in Tsc2−/− MEFs. The Tsc2−/− MEFs were particularly sensitive to nelfinavir treatment (either as a single agent or in combination with bortezomib), resulting in a 2.5-3.3-fold higher level of Chop expression and a 1.8-2.2-fold higher level of Bip expression compared to treatment-matched Tsc2+/+ cells. Bortezomib also induced a threefold increase in Chop mRNA and a 2.4-fold increase in Bip mRNA in the Tsc2−/− cells compared to the control cells. These data demonstrate that both nelfinavir and bortezomib treatment induce a higher ER stress burden in Tsc2-deficient cells. The PERK inhibitor, GSK2606414, markedly repressed CHOP expression induced by nelfinavir and bortezomib, revealing that these drugs induce an ER stress response through PERK (Fig. 1d) .
Given that bortezomib promotes ER stress via proteasomal inhibition and nelfinavir was reported to inhibit the proteasome [16] , we examined proteasome activity through either detection of polyubiquitinated protein (Fig. 1a) , or levels of chymotrypsin-like activity (Fig. 1e) . As expected, bortezomib treatment greatly enhanced the levels of polyubiquitinated protein and effectively reduced chymotrypsin-like activity, indicating robust proteasome inhibition. At 20 µM, nelfinavir did not show proteasome inhibition in either assay.
Elevation of protein synthesis by mTORC1 hyperactivation likely drives ER stress in Tsc2-deficient cells, but has not been examined to date. We analyzed de novo protein synthesis using pulse-chase [ 35 S]-methionine labeling experiments of Tsc2+/+ and Tsc2−/− cells in the presence or absence of nelfinavir and bortezomib (Fig. 1f) . Tsc2−/− Fig. 1 Nelfinavir markedly enhances ER stress in Tsc2−/− MEFs when combined with proteasome inhibitors. a Tsc2+/+ and Tsc2−/− MEFs were treated for 6 h with either DMSO vehicle, 20 µM nelfinavir (NFV), 1 µM MG132, 50 nM bortezomib (BTZ), alone or in combination where indicated. Cells were harvested and total protein levels of TSC2, IRE1α, ATF4, CHOP, GADD34, and β-actin were detected by western blot. Anti-ubiquitin antibodies were used to determine the relative level of polyubiquitinated protein (n = 3). b Xbp1 mRNA splicing was determined following treatments as indicated. PCR products were resolved on agarose gels (unspliced = 480 bp upper band, spliced = 454 bp lower band, n = 3). The proportion of spliced Xbp1 (Xbp1s) is graphed below. c Chop and Bip mRNA levels were analyzed following 6 h dual treatment and standardized against Actb mRNA (n = 3). d Tsc2−/− MEFs were pretreated with 2 μM GSK2606414 (PERK inhibitor) for 30 min, where indicated, before being treated with 20 µM nelfinavir and 50 nM bortezomib for 6 h. Protein expression for CHOP and β-actin was then determined by western blot analysis (n = 3). e The proteasome activity of drug-treated samples, as indicated, was determined by monitoring the turnover of the fluorescent chymotrypsin-like substrate (n = 3). Statistics given are relative to the Tsc2+/+ DMSO control. f Levels of protein synthesis were determined for control, single and dual treated cells as indicated (n = 5) cells had almost fourfold elevation of protein synthesis compared to wild-type, showing that basally ER-stressed Tsc2−/− cells maintain a high level of protein synthesis. After 6 h of nelfinavir and bortezomib dual treatment, protein translation was markedly reduced.
Proteasome inhibition induced death of Tsc2-deficient cells which is enhanced by nelfinavir
We speculated that combined nelfinavir and bortezomib treatment might selectively induce cell death in Tsc2−/− MEFs compared to Tsc2 +/+ MEFs. We quantified cell death by flow cytometry with DRAQ7 labeling, which measures cell death via increased membrane permeability (Fig. 2a, b) . Both MG132 and bortezomib caused selective cell death in the Tsc2−/− MEFs but not in Tsc2+/+ MEFs, revealing that cells devoid of Tsc2 are dependent on the proteasome for their survival. Combined nelfinavir and bortezomib treatment enhanced cell death in the Tsc2−/− MEFs (83.2% ± 9.2 cell death), with minimal toxicity in the Tsc2+/+ MEFs (17.5% ± 7.7). The low level of cell death in the Tsc2+/+ MEFs is not significantly different to the DMSO control. A similar pattern was observed for the nelfinavir/MG132 combination. To validate these findings, we utilized Tsc2-deficient and re-expressing ELT3 rat smooth muscle cells [17] . These results mirrored that seen in the Tsc2−/-MEFs (Supplementary Figure 1A and 1B) .
To further examine cell death we quantified DNA fragmentation (Fig. 2c) . We observed significant DNA fragmentation in Tsc2−/− MEFs after bortezomib treatment that was further enhanced when combined with nelfinavir. No DNA fragmentation was evident with nelfinavir treatment alone. Additionally, we observed cleavage of caspase 8, caspase 3, and PARP in Tsc2−/− MEFs upon treatment with bortezomib alone or cotreatment with nelfinavir and proteasome inhibitors, while no marked cleavage was seen in wild-type cells (Supplementary Figure 1C) . We could partially but significantly rescue Tsc2−/− MEFs from nelfinavir/bortezomib-induced cell death by inhibiting apoptosis with the pan caspase inhibitor, Z-VAD-FMK, suggesting cell death is partly mediated through caspase activation (Fig. 2d) . To determine whether other sporadic cancer cell lines were sensitive to combined nelfinavir and bortezomib treatment, we examined human NCI-H460 lung cancer and HCT116 colon cancer cell lines, which both have elevated levels of mTORC1 signaling. Both cell lines showed sensitivity to the treatment (Fig. 3a, b) . Combined treatment caused cell death at levels of 58.1% ± 18.5 in NCI-H460 cells and 55.1% ± 5.8 in HCT116 cells, significantly higher than with either agent alone. Both cell lines showed a higher level of caspase 8, caspase 3, and PARP cleavage following dual treatment when compared to single drug treatments (Fig. 3c ). Elevated levels of CHOP and GADD34 were observed in nelfinavir-and bortezomib-treated cells, suggesting that cell death was likely mediated through the ER stress pathway.
Synergy of nelfinavir and bortezomib in inducing cell death in Tsc2−/− MEFs
We next assessed synergy between nelfinavir and bortezomib to induce cell death. Tsc2+/+ and Tsc2−/− MEFs were treated with nelfinavir and bortezomib at a range of concentrations, both individually and in combination. Cells were analyzed by flow cytometry using DRAQ7 ( Fig. 4a-d ) revealing that nelfinavir has little cytotoxicity as a single agent, especially at low doses ( Fig. 4a) , while bortezomib potently induces cell death, more so in Tsc2−/− than Tsc2 +/+ cells (Fig. 4b) . While Tsc2+/+ MEFs tolerated high concentrations of nelfinivir and bortezomib in combination ( 
Nelfinavir and bortezomib inhibit tumor spheroid formation and outgrowth of Tsc2−/− cells
Based on the concentrations that demonstrated synergy in Tsc2-/-MEFs, we utilized 20 nM bortezomib with 20 µM nelfinavir in tumor formation assays. Nelfinavir alone did not impact colony formation and growth, but bortezomib treatment impaired growth by 36 ± 12% (Fig. 5a ). When bortezomib was combined with nelfinavir, tumor growth was completely inhibited. To investigate whether nelfinavir and bortezomib could kill established tumors, Tsc2−/− MEFs were cultured as spheroids using 3D cell culture before being treated over 96 h. Nelfinavir and bortezomib as single drug treatments and in combination were compared to the mTORC1 inhibitor, rapamycin. Due to the prolonged time of treatment compared to 2D experiments, we used lower concentrations of nelfinavir (10 μM) and bortezomib (10 nM). Cell death was measured by DRAQ7 staining (Fig. 5b ) and compared to spheroid size (Fig. 5c) . Combined nelfinavir and bortezomib treatment caused a significant increase in DRAQ7 staining compared to both the single drug treatments and rapamycin. Rapamycin visibly shrank overall spheroid size, whereas treatments with either nelfinavir or bortezomib did not. To further determine viability, treated spheroids shown in Fig. 5b were plated into 2D cell culture systems and allowed to regrow without the presence of drug. Spheroid outgrowth was measured over 72 h (Fig. 5d, graphed in 5E ). Rapamycin-treated spheroids, although shrunken, still contained viable cells that rapidly grew out into culture. Spheroids treated with either nelfinavir or bortezomib also grew back, while there was no evidence of outgrowth in the combined nelfinavir and bortezomib treatment. The lack of cell recovery and the high level of DRAQ7 staining indicate that combined treatment with nelfinavir and bortezomib effectively prevents re-growth of spheroids through induction of cell death, whereas rapamycin shrank spheroids that then regrew when treatment was withdrawn, as previously reported in clinical studies with rapalogues [18, 19] . The effect of nelfinavir and bortezomib in Tsc2−/− MEFs was validated in ELT3-V3 cells that showed a similar response (Supplementary Figure S2A -C). To further investigate how drugs affected tumor size and integrity, phalloidin (green) was used to stain the actin cytoskeleton, and DRAQ7 (far red) to counterstain nuclei, following drug treatment of Tsc2−/− MEFs. Figure 5f shows that rapamycin-treated spheroids retain a similar degree of actin fluorescence as DMSO-treated controls, whereas nelfinavir and bortezomib-treated spheroids exhibit Images of the colonies were taken and the diameters measured using ImageJ. Scale bar is 20 µm (n = 4, with >100 spheroids measured per condition, per replicate). b Tsc2−/− MEF spheroids were treated with DMSO vehicle control, 10 μM nelfinavir combined with 10 nM bortezomib (NFV BTZ), or 25 nM rapamycin (RAP), for 96 h. DRAQ7 was added for the final 36 h to monitor cell death before images were taken and quantified (n ≥ 3, average of 12 spheroids per condition per replicate). c Spheroid diameter was determined from phase contrast images of (b) after 96 h drug treatment and plotted against DRAQ7 staining intensity. d Spheroids were re-plated onto standard tissue culture plates and grown under drug-free conditions. Images were taken every 24 h and the area of outgrowth calculated using ImageJ. Scale bar is 200 µm. Relative outgrowth areas are graphed in (e). Statistics compare the 72 h timepoint. Graphs in (a), (b), and (e) shown mean ± S.E.M. f Treated spheroids were stained using phalloidin (actin-green in merged images) and DRAQ7 (nuclei-white) and imaged using confocal microscopy. A representative slice (×63 oil lens) through the spheroid is shown with a scale bar of 30 µm, alongside the maximum projection (×20 lens) with a scale bar of 75 µm comparatively less actin and nuclear staining. The weak nuclear staining and the collapse of the nuclear envelope is indicative of DNA fragmentation and suggests that nelfinavir −bortezomib is killing cells rather than causing senescence. These data support our findings showing that rapamycin shrinks tumors, but without cytotoxic effects, while nelfinavir −bortezomib treatment is effective at causing cell death.
Nelfinavir and bortezomib downregulates prosurvival and upregulates proapoptosis genes, likely mediated through ER stress
To better understand the early changes that nelfinavir and bortezomib cause to gene expression, RNA sequencing was performed in Tsc2+/+ and Tsc2−/− MEFs after 6 h of combined treatment or DMSO control. Figure 6a shows genes associated with ER stress, a selection of which is highlighted graphically in Fig. 6b (raw data in Supplementary Table 1) . Tsc2−/− MEFs expressed higher basal levels of ER stress genes shown in the panel (Fig. 6a, Supplementary Figure S3A and Supplementary Table 2) . Following nelfinavir and bortezomib treatment, expression was further increased (Supplementary Figure S3B and Supplementary Table 3) , with expression in Tsc2−/− cells mostly significantly higher than that of the Tsc2+/+ MEFs (Fig. 6b) . Figure 6c describes the changes of prosurvival and prodeath genes in Tsc2+/+ vs. Tsc2−/− dual-treated MEFs (genes selected based on AmiGO "cell death"). Figure 6c shows expression of prosurvival genes to be decreased, and prodeath genes to be increased in drug-treated Tsc2−/− cells compared to treated Tsc2+/+ MEFs. The overall RNA sequencing data are shown in a volcano plot (Fig. 6d and Supplementary Table 4) , with the genes in Fig. 6c highlighted. To validate that Tsc2+/+ MEFs could efficiently restore ER homeostasis, while Tsc2 −/− MEFs could not, we carried out a time course of nelfinavir−bortezomib treatment (Fig. 6e) . We observed a strong increase in ATF4 and CHOP protein in both cell lines at 6 h of treatment, which was downregulated by 16 h to a level that was not significantly different to untreated. However, after 24 h of treatment, the protein expression of ATF4 and CHOP was enhanced in the Tsc2−/− MEFs, suggesting an inability to efficiently restore ER homeostasis. In contrast, the protein levels of ATF4 and CHOP remained low in the Tsc2+/+ MEFs after 24 h.
Nelfinavir and bortezomib reduced tumor volume in ELT-V3 mouse xenografts, correlating with increased CHOP expression
To determine the antitumor efficacy of nelfinavir and bortezomib in vivo, mice bearing Tsc2-null ELT3 xenograft tumors were treated with the drugs as single agents or in combination. Seventeen days after commencement of treatment, combined nelfinavir and bortezomib decreased tumor growth by approximately 70% which was a significant decrease compared with vehicle-treated mice (Fig.  7a) . The single agent treatments slowed tumor growth but not significantly. While combined treatment of nelfinavir and bortezomib is well tolerated in patients [11] , it was not well tolerated in mice. In the combination group, 11/14 mice died or were euthanized due to excessive toxicity compared with 2/14 in the vehicle-treated group, 5/14 in the nelfinavir-alone group and 5/14 in the bortezomib-alone group. Immunohistochemical analysis of xenograft tumor tissue sections revealed a modest increase in CHOP-positive cells after nelfinavir and bortezomib combined treatment (Fig. 7b) . The heterogeneity of CHOP staining likely reflects cycles of ER stress induction and recovery in these cells. By western blot analysis, a higher level of ATF4 protein and PARP cleavage was observed in tumors from mice that were treated with both nelfinavir and bortezomib (Fig. 7c) , indicating an elevated level of ER stress and cell death upon combined treatment.
Discussion
This study uses clinically relevant drugs that could be repositioned to treat tumors displaying high ER stress and mTORC1. We reveal that mTORC1-overactive cells are sensitive to nelfinavir and bortezomib treatment. Nelfinavir and bortezomib act to amplify ER stress and synergize to promote cell death. While wild-type cells tolerate this drug combination with minimal cell death, cytotoxicity in Tsc2-deficient cells is evident at low drug concentrations and is likely attributable to their inability to manage ER stress. Indeed, we see that ER stress is not fully restored in the Tsc2-deficient cells after 24 h of combined drug treatment, as observed by a reoccurrence of ATF4 and CHOP protein expression (Fig. 6e) . Tsc2-deficient cells were reported to have a truncated ER stress response [20] , which fits with our observation that cells lacking functional Tsc2 are compromised in their ability to restore ER homeostasis. TSC2 functions as an important component of the survival arm during ER stress as it is positioned downstream of several ER stress-mediated survival pathways. One pathway involves GADD34, which recruits protein phosphatase 1 (PP1) to TSC2, dephosphorylating and activating TSC2 to repress mTORC1. We observed high protein levels of GADD34 after ER stress induction in all our cell lines, more so in Tsc2−/− MEFs.
Normally, protein synthesis is downregulated upon ER stress as a strategy to prevent further build-up of unfolded protein within the ER. We observed that Tsc2-deficient cells have elevated protein synthesis despite higher background levels of ER stress, with a 3-4-fold increase in protein synthesis in Tsc2−/-MEFs compared to wild-type (Fig. 1f ). Elevated levels of protein synthesis likely enhances ER stress within the Tsc2-deficient cells. As well as promoting translation, mTORC1 hyperactivation increases the activity of the proteasome while inhibiting autophagy [6] . Downregulation of autophagy means that the proteasome becomes the principal mechanism to reduce ER stress via protein degradation in cells lacking Tsc2. However, the proteasome inhibitor, bortezomib, had a lack of in vivo activity against renal tumors in Tsc2+/− mice as a single agent [9] , perhaps reflecting a failure to induce a sufficient level of ER stress. This problem could potentially be overcome by combining two ER stress inducing agents, such as nelfinavir and bortezomib. Bortezomib (Velcade, Janssen-Cilag) was the first FDAapproved proteasome inhibitor that showed clinical promise for treating cancer. Bortezomib was approved for advanced multiple myeloma and more recently for mantle cell lymphoma. Next-generation proteasome inhibitors (marizomib and carfilzomib) are currently in clinical trials. Bortezomib's specifically binds the catalytic site of the 26S proteasome to inhibit enzyme activity. By inhibiting the ubiquitin-proteasome system, bortezomib markedly alters the survival status of cancer cells. The synergy observed between nelfinavir and bortezomib is unlikely due to ER stress alone, but probably involves other processes. Additional processes affected upon proteasome inhibition include cell cycle control, apoptosis, angiogenesis, transcriptional regulation, and DNA-damage response (see review [21] ). Although the nelfinavir and bortezomib combination showed considerable toxicity in mice in our study, a recent phase I clinical trial (clinicaltrials.gov: NCT01164709) in bortezomib-refractory multiple myeloma combining bortezomib with nelfinavir was well tolerated, safe and showed activity [11] . A phase II trial of advanced hematological malignancies showed that nine relapse patients whose malignancies were resistant to bortezomib had either a partial response or clinical benefit when bortezomib was combined with nelfinavir, with no apparent increase in toxicity [11] .
Our work demonstrates for the first time that functional loss of TSC2 and subsequent mTORC1 hyperactivation sensitizes cells to combined proteasomal inhibition and ER stress. Our findings have clinical relevance in stratified medicine, where cancers with compromised signal transduction through TSC1/2-mTORC1 (via upstream pathways, e.g., oncogenic K-RAS or loss of PTEN) may be sensitive to nelfinavir and bortezomib. Our data imply that a high ER stress burden and hyperactive mTORC1 could function as 
Materials and methods
Cell culture and reagents
Tsc2+/+ p53−/− and Tsc2−/− p53−/− MEFs were kindly provided by D. Kwiatkowski in 2004 (Harvard University, Boston, USA) [22] . Eker rat leiomyoma-derived Tsc2-deficient cells (ELT3-V3) and matched controls reexpressing Tsc2 (ELT3-T3) were generated by Astrinidis et al. [17] and were gifted in 2006 by C. Walker (M.D. Anderson Cancer Center, Houston, USA). HCT116 cells were provided by N. Leslie (Heriot Watt University, Edinburgh) in 2015, while human lung carcinoma (NCI-H460) cells were bought from ATCC (in 2012). All cell lines were regularly screened for mycoplasma using the Venor GeM Classic PCR kit (CamBio) and were mycoplasma free. Cells were cultured in Dulbecco's modified Eagle's medium (BE12-604F, Lonza, Basel, Switzerland) supplemented with 10% (v/v) foetal bovine serum (10270106, Thermo Fisher Scientific), 100 U/ml penicillin and 100 µg/ml streptomycin (P4333, Sigma-Aldrich, Dorset, UK) at 37°C, 5% (v/v) CO 2 . Nelfinavir mesylate hydrate (PZ0013), MG132 (C2211), thapsigargin (T9033), and etoposide (E1383) were purchased from Sigma. Bortezomib (CAS 179324-69-7), rapamycin (CAS 53123-88-9), Z-VAD-FMK (CAS 161401-82-7), and GSK2606414 were from Merck Millipore (Hertfordshire, UK).
mRNA extraction, reverse transcription, XBP1 splicing, Chop, and Bip qPCR Samples were prepared and analyzed as described previously [15] . Bip was analyzed using Quantitect primers (QT00172361, Qiagen).
Western blotting
Cells were washed in PBS and lysed in radio immunoprecipitation assay (RIPA) buffer (R0278) supplemented with Complete Mini protease inhibitor cocktail (11836170001), PhosSTOP phosphatase inhibitor cocktail (04906837001) and 1 mM dithiothreitol (DTT, D0632) (all from Sigma). Detached dead cells in the media and PBS wash were collected by centrifugation for 5 min at 5000 rpm and combined with the lysate. After sonication, equal protein amounts were loaded on SDS-PAGE and western blotting was performed as described previously [23] . Protein from xenografts was extracted using the AllPrep DNA/RNA/Protein Mini Kit (Qiagen). Antibodies towards C/EBP homologous protein (CHOP, #2895), inositol-requiring and ER-to-nucleus signaling protein 1α (IRE1α, #3294S), ATF4 (#11815), caspase 3 (#9662), caspase 8 (mouse specific #4927, human specific #9746), PARP (#9542), TSC2 (#3990), and β-actin (#4967) were purchased from Cell Signaling Technology (Danvers, USA). Growth arrest and DNA damage-inducible protein 34 (GADD34, also known as Protein phosphatase 1 regulatory subunit 15A [PPP1R15A], 10449-1-AP) antibodies were bought from Proteintech (Manchester, UK). Ubiquitin antibodies were from BioMol (PW8810). Densitometry was performed using ImageJ (version 1.51j8).
Late cell death assay and determination of drug synergy
Cell death assays were performed as previously described [15] . To determine synergy, a range of drug concentrations was used and the CI values were calculated using CompuSyn software (ComboSyn, Inc.) using a non-constant ratio approach.
DNA fragmentation ELISA
DNA fragmentation was determined with the Cell Death Detection ELISA kit (Roche). Immobilized histone complex was quantified photometrically (at 405 nm) using 2,2,0-azino-bis-3-ethylbenzothiazoline-6-sulfonic acid as a peroxidase substrate.
Proteasome activity analysis
Proteasomes were extracted 2 h post-treatment and their chymotrypsin-like proteasome activity determined as described [24] .
Soft agar assay, spheroids, and outgrowth
Soft agar assays, spheroid formation, and outgrowth analysis were performed as described [25] . For phalloidin staining, spheroids were fixed in 4% paraformaldehyde for 30 min. Spheroids were permeabilized using 0.1% Triton-X100 for 45 min before being stained with ActinGreen 488 Ready Probes Reagent (R37110, Thermo Fisher). Spheroids were stained with 3 μM DRAQ7 (DR71000, Biostatus), transferred to a glass-bottomed plate, imaged using a Zeiss LSM 880 confocal microscope with Zen software and then analyzed using ImageJ v1.50i.
RNA-Seq sample preparation, sequencing, and analysis RNA quality was assessed using Agilent 2100 Bioanalyser and an RNA Nano 6000 kit (Agilent Technologies). 
ELT-3 mouse xenograft
Animal experimental procedures were approved by the Institutional Animal Care and Use Committee of CrownBIO. Care and use of animals was conducted in accordance with the regulations of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC). A mouse xenograft model was established using ELT3-V3 cells inoculated into 9-10-week-old female NOD/SCID mice (HFK Bio-Technology Co. Ltd. (Beijing, China)). Sample size was based upon using a two-tailed t test, assuming unequal variance and large effect size of 0.8 with 60% power at the 10% significance level. Exponentially growing ELT3-V3 cells were used for tumor inoculation. One week before cell inoculation, mice were implanted with 17-β-estradiol pellets (2. ; where a and b are the long and short diameters of the tumor, respectively). Grouping and treatments began after the mean tumor size reached 186 mm 3 . Fourteen mice were assigned per treatment group using a randomized block design, based on their tumor volumes to receive either: (1) vehicle (4% (v/v) DMSO, 5% (v/v) PEG, 5% (v/v) TWEEN 80 in saline); (2) nelfinavir, 50 mg/kg dissolved in vehicle; (3) bortezomib, 0.5 mg/kg dissolved in 0.04% (v/v) mannitol solution; or (4) nelfinavir, 50 mg/kg and bortezomib, 0.5 mg/kg. Treatments were administered intraperitoneally on days 1, 3, 5, 8, 10, 12, 15 and 17. Dosages were reduced to 30 mg/kg nelfinavir and 0.3 mg/kg bortezomib on day 8 due to toxicity. Tumor volumes were measured three times per week. Investigators were not blinded to the group allocation. Due to lower numbers of mice than anticipated at day 17, groups were compared nonparametrically using the Kruskal−Wallis test and pairwise comparisons.
Immunohistochemistry
Tumors in optimal cutting temperature compound were snap frozen and cryostat sectioned at 10 µm thickness. Sections were warmed to room temperature for 30 min, fixed in ice-cold acetone (5 min) and air-dried (30 min). After blocking in 5% (v/v) normal goat serum in TrisBuffered Saline (pH 7.6) 0.1% (v/v) Tween-20, sections were incubated at 4°C with 1/1000 rabbit monoclonal antibody against CHOP (Abcam, ab179823) overnight, blocked with Envision peroxidase block and incubated for 30 min in Envision rabbit polymer, before detection with DAB chromogen (all DAKO). Slides were hematoxylin counterstained, dehydrated through an ethanol series and xylene, before mounting in DPX medium (Fisher Scientific). Five fields from each tumor were scored for % of CHOP-positive cells (ImageJ, v1.51j8).
Statistical analysis
At least three independent, biological repeats were performed for each experiment. Exact sample size is indicated in each figure legend. Results are expressed as mean ± standard deviation (SD), unless otherwise specified in the figure legend. Data analysis was carried out using a oneway ANOVA followed by LSD post-hoc test, or an independent samples Kruskal−Wallis test as appropriate. Significance is reported at *p < 0.05, **p < 0.01, ***p < 0.001, and NS = not significant.
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